Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Pentoxifylline 400 mg Sustained Release Tablets
NCT06823362Phase 4Not yet recruiting
- Sponsor
- CAIMED
- Start
- Apr 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of pentoxifylline in peripheral vascular disease (PVD), sponsored by CAIMED. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
pentoxifylline
03
Conditions
peripheral vascular disease (PVD)
Beyond the preview
Go deeper on NCT06823362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823362.